Cornerstone Therapeutics, Inc. (CRTX) Tops Q2 EPS by 5c, Revenues Beat Expectations
Tweet
Share
E-mailGet Alerts CRTX Hot Sheet
Price: $1.95 --0%
Financial Fact:
Income (loss) before income taxes: 14.25M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Income (loss) before income taxes: 14.25M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) reported Q2 adjusted EPS of $0.11, $0.05 better than the analyst estimate of $0.06. Revenue for the quarter came in at $28.04 million versus the consensus estimate of $25.71 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
